Qiagen NV Releases Transcript for Second Quarter 2025 Results Call

Reuters

2025/08/22

Qiagen NV Releases Transcript for Second Quarter 2025 Results Call

Qiagen NV recently held a call to discuss their second quarter 2025 results, hosted by John Gilardi, Vice President of Corporate Communications. The call was attended by Thierry Bernard, Chief Executive Officer, Roland Suckers, Chief Financial Officer, and Dr. Domenico Mortorona from the Investor Relations team. The management highlighted several key points during the call. They emphasized their strong performance and upgraded their full-year 2025 net sales outlook, citing a "solid start to the year." They also reaffirmed their adjusted EPS target. The CEO noted their commitment to "advancing our capital allocation that balances investments in QIAGEN with increasing shareholder returns." Additionally, the company is focusing on innovation, digital infrastructure, and strategic M&A deals. The call also highlighted ongoing collaborations in oncology and precision medicine, including a global partnership with Incyte to develop an NGS-based test for bone marrow cancer. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2561834421"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561834421\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561834421?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 15:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561834421","market":"fut","top_or_hot":-1,"title":"Qiagen NV Releases Transcript for Second Quarter 2025 Results Call","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qiagen NV Releases Transcript for Second Quarter 2025 Results Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qiagen NV recently held a call to discuss their second quarter 2025 results, hosted by John Gilardi, Vice President of Corporate Communications. The call was attended by Thierry Bernard, Chief Executive Officer, Roland Suckers, Chief Financial Officer, and Dr. Domenico Mortorona from the Investor Relations team. The management highlighted several key points during the call. They emphasized their strong performance and upgraded their full-year 2025 net sales outlook, citing a \"solid start to the year.\" They also reaffirmed their adjusted EPS target. The CEO noted their commitment to \"advancing our capital allocation that balances investments in QIAGEN with increasing shareholder returns.\" Additionally, the company is focusing on innovation, digital infrastructure, and strategic M&amp;A deals. The call also highlighted ongoing collaborations in oncology and precision medicine, including a global partnership with Incyte to develop an NGS-based test for bone marrow cancer. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qiagen NV Releases Transcript for Second Quarter 2025 Results Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQiagen NV Releases Transcript for Second Quarter 2025 Results Call\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-22 15:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qiagen NV Releases Transcript for Second Quarter 2025 Results Call\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qiagen NV recently held a call to discuss their second quarter 2025 results, hosted by John Gilardi, Vice President of Corporate Communications. The call was attended by Thierry Bernard, Chief Executive Officer, Roland Suckers, Chief Financial Officer, and Dr. Domenico Mortorona from the Investor Relations team. The management highlighted several key points during the call. They emphasized their strong performance and upgraded their full-year 2025 net sales outlook, citing a \"solid start to the year.\" They also reaffirmed their adjusted EPS target. The CEO noted their commitment to \"advancing our capital allocation that balances investments in QIAGEN with increasing shareholder returns.\" Additionally, the company is focusing on innovation, digital infrastructure, and strategic M&amp;A deals. The call also highlighted ongoing collaborations in oncology and precision medicine, including a global partnership with Incyte to develop an NGS-based test for bone marrow cancer. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"紅杉資本持倉","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL4hwZ5W:1","article_id":"2561834421","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561834421","pubTimestamp":1755849540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Qiagen NV recently held a call to discuss their second quarter 2025 results, hosted by John Gilardi, Vice President of Corporate Communications. The call was attended by Thierry Bernard, Chief Executive Officer, Roland Suckers, Chief Financial Officer, and Dr. Domenico Mortorona from the Investor Relations team. The management highlighted several key points during the call. They emphasized their strong performance and upgraded their full-year 2025 net sales outlook, citing a \"solid start to the year.\" They also reaffirmed their adjusted EPS target. The CEO noted their commitment to \"advancing our capital allocation that balances investments in QIAGEN with increasing shareholder returns.\" Additionally, the company is focusing on innovation, digital infrastructure, and strategic M&A deals. The call also highlighted ongoing collaborations in oncology and precision medicine, including a global partnership with Incyte to develop an NGS-based test for bone marrow cancer. The full transcript ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","BK4588":"碎股","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","QGEN":"快而精医药","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","BK4121":"生命科学工具和服务","LU1923622614.USD":"Natixis Thematics Meta R/A USD"},"translate_title":"Qiagen NV发布看涨期权2025年第二季度业绩记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9,"QGEN":0.9},"content_text":"Qiagen NV Releases Transcript for Second Quarter 2025 Results Call\n    \n\n        Qiagen NV recently held a call to discuss their second quarter 2025 results, hosted by John Gilardi, Vice President of Corporate Communications. The call was attended by Thierry Bernard, Chief Executive Officer, Roland Suckers, Chief Financial Officer, and Dr. Domenico Mortorona from the Investor Relations team. The management highlighted several key points during the call. They emphasized their strong performance and upgraded their full-year 2025 net sales outlook, citing a \"solid start to the year.\" They also reaffirmed their adjusted EPS target. The CEO noted their commitment to \"advancing our capital allocation that balances investments in QIAGEN with increasing shareholder returns.\" Additionally, the company is focusing on innovation, digital infrastructure, and strategic M&A deals. The call also highlighted ongoing collaborations in oncology and precision medicine, including a global partnership with Incyte to develop an NGS-based test for bone marrow cancer. The full transcript can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief on August 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}